Pharma Law Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Pharma Law Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Cytopia
Cytopia announces major license and R&D collaboration
July 4th, 2006
Cytopia Ltd announced the signing of a global license and research and development collaboration with Novartis to develop orally active, small molecule therapeutics targeting JAK3 kinase for the prevention of transplant rejection and the treatment of multiple indications in autoimmune diseases such as rheumatoid arthritis. Both companies will contribute expertise and intellectual property relating to JAK3 inhibitors for the purpose of bringing compounds into the clinic. Novartis will assume responsibility for product development and commercialization. Cytopia has retained co-promotion rights for Australia and New Zealand. "This deal is an important...
Source: Pharma Law Weekly (2006-07-04)
|
